Regeneron
regeneron.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
For 30 years, our mission has been to use the power of science to bring new medicines to patients.... over and over again. Every day, we apply our homegrown technologies and relentless spirit to help people with serious diseases.
News
Regeneron's Semaglutide Plus Trevogrumab Combo Demonstrates Superior Fat Loss with Reduced Muscle Wasting in Obesity Trial PharmExec
Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves lean mass and enhances fat loss, offering a potential advancement in obesity treatment.
Read more
Report
REGN Stock Drop: If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Leading the Class Action Lawsuit
Read more
Report
Regeneron stock rises after strong Q2 2026 beat (REGN:NASDAQ)
Regeneron (REGN) stock gains after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates due mainly to higher Eylea HD sales. Read more here.
Read more
Report
Pro access
Upgrade to see all 37 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Growth
Hiring Momentum
28/100
Slowing
Open positions
0
0 opened / 0 closed in 30 days
Hiring Dynamics
0%